The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies
Open accessAbstract
Background Whether triglyceride-mediated pathways are causally relevant to coronary heart disease is uncertain. We studied a genetic variant that regulates triglyceride concentration to help judge likelihood of causality.Methods We assessed the -1131T>C (rs662799) promoter polymorphism of the apolipoprotein A5 (APOA5) gene in relation to triglyceride concentration, several other risk factors, and risk of coronary heart disease. We compared disease risk for genetically-raised triglyceride concentration (20,842 patients with coronary heart disease, 35,206 controls) with that recorded for equivalent differences in circulating triglyceride concentration in prospective studies (302 430 participants with no history of cardiovascular disease; 12,785 incident cases of coronary heart disease during 2.79 million person-years at risk). We analysed -1131T>C in 1795 people without a history of cardiovascular disease who had information about lipoprotein concentration and diameter obtained by nuclear magnetic resonance spectroscopy.Findings The minor allele frequency of -1131T>C was 8% (95% CI 7-9). -1131T>C was not significantly associated with several non-lipid risk factors or LDL cholesterol, and it was modestly associated with lower HDL cholesterol (mean difference per C allele 3.5% [95% CI 2.6-4.6]; 0.053 mmol/L [0.039-0.068]), lower apolipoprotein AI (1.3% [0.3-2.3]; 0.023 g/L [0.005-0.041]), and higher apolipoprotein B (3.2% [1.3-5.1]; 0.027 g/L [0.011-0.043]). By contrast, for every C allele inherited, mean triglyceride concentration was 16.0% (95% CI 12.9-18.7), or 0.25 mmol/L (0.20-0.29), higher (p=4.4x10(-24)). The odds ratio for coronary heart disease was 1.18 (95% CI 1.11-1.26; p=2.6x10(-7)) per C allele, which was concordant with the hazard ratio of 1.10 (95% CI 1.08-1.12) per 16% higher triglyceride concentration recorded in prospective studies. -1131T>C was significantly associated with higher VLDL particle concentration (mean difference per C allele 12.2 nmol/L [95% CI 7.7-16.7]; p=9.3x10(-8)) and smaller HDL particle size (0.14 nm [0.08-0.20]; p=7.0x10(-5)), factors that could mediate the effects of triglyceride.Interpretation These data are consistent with a causal association between triglyceride-mediated pathways and coronary heart disease.Funding British Heart Foundation, UK Medical Research Council, Novartis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the role of TG as a risk factor for CVD has been strongly debated, recent data strongly favour the role of TG-rich lipoproteins as a risk factor for CVD.121”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [121]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Non-HDL-C also includes the atherogenic TG-rich lipoproteins (VLDL, IDL and remnants), which is essential considering the recent information from genome-wide association studies (GWASs) and Mendelian randomization 76,86 - 89 supporting TGs and remnant particles as causative factors in atherogenesis.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the CVD risk is increased if fasting TGs are . 1.7 mmol/ L (150 mg/dL), 87 the use of drugs to lower TGs may only be considered in high-risk subjects when TGs are . 2.3 mmol/L (200 mg/dL) and cannot be lowered by lifestyle measures.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results of the current study extend those findings by suggesting that triglyceride-rich remnant particles have approximately the same effect on the risk of cardiovascular disease as LDL particles.”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [28]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The association between triglycerides and cardiovascular (CV) risk is well established from epidemiological studies,1-5 genome-wide analyses,6-8 and Mendelian randomization studies.9,10”
In the citing paper
“Therefore, the clinical benefit of therapies that lower LDL-C by reducing LDL particle mass will be proportional to the absolute reduction in LDLC, because-on average-the reduction in LDL-C and LDL particles will be concordant [34,50,54,55].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [55]
In the citing paper
“The beneficial effect of ezetimibe is also supported by genetic studies of mutations in NPC1L1; naturally occurring mutations that inactivate the protein were found to be associated with reduced plasma LDL-C and reduced risk for CAD [55,269,270].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [55]
In the citing paper
“The causative role of HDL-C for protection against CVD has been questioned in several studies utilizing Mendelian randomization. 87,89,91,92”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
In the citing paper
“Although the role of TGs as a risk factor for CVD has been strongly debated, recent data favour the role of TG-rich lipoproteins as a risk factor for CVD.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
In the citing paper
“The causative role of HDL-C for protection against CVD has been questioned in several studies utilizing Mendelian randomization.87,89,91,92”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
In the citing paper
“recent data favour the role of TG-rich lipoproteins as a risk factor for CVD.87”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Davey Smith, G., & Ebrahim, S. (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg070 · Cited by 5,882
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Tunstall-Pedoe, H., Kuulasmaa, K., Amouyel, P., Arveiler, D., Rajakangas, A.-M., & Pająk, A. (1994) · Circulation · doi:10.1161/01.cir.90.1.583 · Cited by 2,260
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Kathiresan, S., Melander, O., Guiducci, C., Surti, A., Burtt, N. P., Rieder, M. J., Cooper, G. M., Roos, C., Voight, B. F., Havulinna, A. S., et al. (2008) · Nature Genetics · doi:10.1038/ng.75 · Cited by 1,386
Thompson, A. (2008) · JAMA · doi:10.1001/jama.299.23.2777 · Cited by 498
Sattar, N. A., McConnachie, A., Shaper, A. G., Blauw, G. J., Buckley, B. M., de Craen, A. J. M., Ford, I., Forouhi, N. G., Freeman, D. J., Jukema, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60602-9 · Cited by 492
Keating, B. J., Tischfield, S. E., Murray, S. S., Bhangale, T., Price, T. S., Glessner, J., Galver, L., Barrett, J. C., Grant, S. F. A., Farlow, D., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003583 · Cited by 373
Cited by
Sorted by citations
Items 301–400 of 716
Yang, Y., Kim, H., Kim, S., & Moon, M. K. (2023) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2023.12.1.12 · Cited by 25
Management of Dyslipidemias in the Presence of the Metabolic Syndrome or Type 2 Diabetes
Matikainen, N., & Taskinen, M. (2012) · Current Cardiology Reports · doi:10.1007/s11886-012-0309-3 · Cited by 24
Using Mendelian randomization to determine causative factors in cardiovascular disease
Johansen, C. T., & Hegele, R. A. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02586.x · Cited by 24
Lewis, S. J., Relton, C. L., Zammit, S., & Smith, G. D. (2013) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12127 · Cited by 26
Pharmacogenomics of Lipid-Lowering Therapies
Hu, M., & Tomlinson, B. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.71 · Cited by 24
Novel drugs in familial combined hyperlipidemia: lessons from type 2 diabetes mellitus
Brouwers, M. C. G. J., Graaf, J. D., van Greevenbroek, M. M. J., Schaper, N. C., Stehouwer, C. D. A., & Stalenhoef, A. F. H. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833ea9ec · Cited by 24
Egeland, G. M., Igland, J., Sulo, G., Nygard, O. K., Ebbing, M., & Tell, G. S. (2014) · European Journal of Preventive Cardiology · doi:10.1177/2047487314535681 · Cited by 24
Moderate Alcohol Consumption and Triglyceridemia
Kovář, J., & Zemánková, K. (2015) · Physiological Research · doi:10.33549/physiolres.933178 · Cited by 23
Beyond the Single SNP: Emerging Developments in Mendelian Randomization in the “Omics” Era
Brion, M., Benyamin, B., Visscher, P. M., & Smith, G. D. (2014) · Current Epidemiology Reports · doi:10.1007/s40471-014-0024-2 · Cited by 22
Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype
Sanin, V., Pfetsch, V., & Köenig, W. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0869-3 · Cited by 24
Changes in HDL cholesterol and cardiovascular outcomes after lipid modification therapy
Ray, K. K., Wainwright, N. W. J., Visser, L. E., Witteman, J. C. M., Breteler, M. M. B., Ambegaonkar, B. M., Albert Hofman, D., Stricker, B. H. C., Wareham, N. J., Khaw, K., et al. (2012) · Heart · doi:10.1136/heartjnl-2011-301405 · Cited by 21
Management of Hypertriglyceridemia for Prevention of Atherosclerotic Cardiovascular Disease
Brinton, E. A. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.09.012 · Cited by 22
Yang, Y., Kim, H., Kim, S., Moon, M. K., & Korean Society of Lipid and Atherosclerosis (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0448 · Cited by 24
Management of Hypertriglyceridemia for Prevention of Atherosclerotic Cardiovascular Disease
Brinton, E. A. (2015) · Cardiology Clinics · doi:10.1016/j.ccl.2015.02.007 · Cited by 22
Poornima, I. G., Mackey, R. H., Buhari, A. M., Cauley, J. A., Matthews, K. A., & Kuller, L. H. (2014) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000127 · Cited by 21
Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East
Sayed, N., Waili, K. A., Alawadi, F., Al-Ghamdi, S. M. G., Almahmeed, W. A., Alnouri, F., Rukhaimi, M. A., Al‐Rasadi, K., Awan, Z. A., Farghaly, M., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.09.081 · Cited by 22
Kim, Y., Lee, S., Lee, Y., Kang, M. W., Park, S., Park, S. H., Han, K., Paek, J. H., Park, W. Y., Jin, K., et al. (2020) · Clinical Kidney Journal · doi:10.1093/ckj/sfaa252 · Cited by 21
Grosskopf, I., Shaish, A., Afek, A. B., Shemesh, S., Harats, D., & Kamari, Y. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.04.011 · Cited by 21
Kitagami, M., Yasuda, R., Toma, N., Shiba, M., Nampei, M., Yamamoto, Y., Nakatsuka, Y., Sakaida, H., & Suzuki, H. (2017) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2017.04.010 · Cited by 21
Rosenblat, M., Ward, S., Volkova, N., Hayek, T., & Aviram, M. (2012) · BioFactors · doi:10.1002/biof.1021 · Cited by 20
Evans, D., Aberle, J., & Beil, F. U. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.09.030 · Cited by 20
Low-Density Lipoprotein Triglycerides
Miller, M. J. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.541 · Cited by 20
Proprotein convertase 7 (PCSK7) reduces apoA‐V levels
Ashraf, Y., Duval, S., Sachan, V., Essalmani, R., Susan‐Resiga, D., Roubtsova, A., Hamelin, J., Gerhardy, S., Kirchhofer, D., Tagliabracci, V. S., et al. (2020) · FEBS Journal · doi:10.1111/febs.15212 · Cited by 20
Serum triglycerides and risk for death in Stage 3 and Stage 4 chronic kidney disease
Navaneethan, S. D., Schold, J. D., Arrigain, S., Thomas, G., Jolly, S., Poggio, E. D., Schreiber, M. J., Sarnak, M. J., & Nally, J. V. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs058 · Cited by 20
Zhang, K., Zhao, M. ‐., An, Q., Jia, Y., Fu, L., Xu, J., & Gu, Y. (2017) · Andrology · doi:10.1111/andr.12425 · Cited by 21
Langlois, M. R., & Nordestgaard, B. G. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1036-1 · Cited by 19
Gai, Y., Li, Y., Xu, Z., & Chen, J. (2019) · Fitoterapia · doi:10.1016/j.fitote.2019.104393 · Cited by 19
Jin, D., Trichia, E., Islam, N., Bešević, J., Lewington, S., & Lacey, B. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.029552 · Cited by 19
Ramakrishnan, L., Sachdev, H. S., Sharma, M., Abraham, R. A., Prakash, S., Gupta, D., Singh, Y. R., Bhaskar, S., Sinha, S., Chandak, G. R., et al. (2011) · Lipids in Health and Disease · doi:10.1186/1476-511x-10-68 · Cited by 19
Associations of triglyceride levels with longevity and frailty: A Mendelian randomization analysis
Liu, Z., Burgess, S., Wang, Z., Deng, W., Chu, X., Cai, J., Zhu, Y., Shi, J., Xie, X., Wang, Y., et al. (2017) · Scientific Reports · doi:10.1038/srep41579 · Cited by 19
Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy
Reiner, Ž. (2018) · Korean Circulation Journal · doi:10.4070/kcj.2018.0343 · Cited by 19
Onat, A., Can, G., Çiçek, G., Ayhan, E., & Doğan, Y. (2010) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2010.08.027 · Cited by 19
Song, K. H., Cha, S., Yu, S.-G., Yu, H., Oh, S. A., & Kang, N.-S. (2013) · BioMed Research International · doi:10.1155/2013/585134 · Cited by 19
Yao, W.-M., Zhang, H.-F., Zhu, Z.-Y., Zhou, Y.-L., Liang, N.-X., Xu, D.-J., Zhou, F., Sheng, Y.-H., Yang, R., Gong, L., et al. (2012) · Journal of Human Hypertension · doi:10.1038/jhh.2012.23 · Cited by 19
Editorial Are we getting to lipid targets in real life?
Katsiki, N., Mikhailidis, D. P., Athyros, V. G., Hatzitolios, A. I., Karagiannis, A. I., & Banach, M. (2010) · Archives of Medical Science · doi:10.5114/aoms.2010.17073 · Cited by 18
Richardson, T. G., Mykkänen, J., Pahkala, K., Ala‐Korpela, M., Bell, J. A., Taylor, K., Viikari, J. S. A., Lehtimäki, T. J., Raitakari, O. T., & Smith, G. D. (2020) · medRxiv · doi:10.1101/2020.08.25.20181412 · Cited by 19
Roundtable on etiology of familial chylomicronemia syndrome
Brown, W. V., Gaudet, D., Goldberg, I., & Hegele, R. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2017.12.015 · Cited by 18
Lu, Y., Li, G., Viallon, V., Ferrari, P., Freisling, H., Qiao, Y., Shao, L., Wu, L., Ding, Y., & Ke, C. (2024) · American Journal of Epidemiology · doi:10.1093/aje/kwae167 · Cited by 18
Association of apolipoprotein A5 gene promoter region −1131T>C with risk of stroke in Han Chinese
Li, X., Su, D.-F., Zhang, X., & Zhang, C. (2010) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2010.07.012 · Cited by 18
Sundvall, J., Leiviskä, J., Laatikainen, T. K., Peltonen, M., Salomaa, V. V., Vanhala, M. J., Korpi-Hyövälti, E., Lauronen, J., & Alfthan, G. (2011) · BMC Medical Research Methodology · doi:10.1186/1471-2288-11-63 · Cited by 20
Girelli, D., Piubelli, C., Martinelli, N., Corrocher, R., & Olivieri, O. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.03.019 · Cited by 18
Komatsu, T., Sakurai, T., Wolska, A. T., Amar, M. J., Sakurai, A., Vaisman, B. L., Sviridov, D. O., Demosky, S. J., Pryor, M., Ikewaki, K., et al. (2019) · Journal of Nutrition and Metabolism · doi:10.1155/2019/7078241 · Cited by 18
Takanashi, M., Kimura, T., Li, C., Tanaka, M., Matsuhashi, A., Yoshida, H., Noda, A., Xu, P., Takase, S., Okazaki, S., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311931 · Cited by 18
Gómez-Delgado, F., Alcala-Diaz, J. F., Leon‐Acuña, A., López-Moreno, J., Delgado‐Lista, J., Gomez‐Marin, B., Roncero‐Ramos, I., Yubero‐Serrano, E. M., Rangel-Zúñiga, O. A., Vals‐Delgado, C., et al. (2019) · European Journal of Clinical Investigation · doi:10.1111/eci.13146 · Cited by 18
Wang, J., Xiang, D., Mei, S., Jin, Y., Sun, D., Chen, C., Hu, D., Li, S., Li, H., Wang, Y., et al. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.100996 · Cited by 19
Wang, C., Enssle, J., Pietzner, A., Schmöcker, C., Weiland, L., Ritter, O., Jaensch, M., Elbelt, U., Pagonas, N., & Weylandt, K. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020766 · Cited by 18
Catalina Dussaillant, K., Serrano, V., Alberto Maiz, G., Eyheramendy, S., Cataldo, L. R., Chavez, M., Smalley, S. V., Fuentes, M., Rigotti, A., Rubio, L., et al. (2012) · BMC Medical Genetics · doi:10.1186/1471-2350-13-106 · Cited by 20
Hermans, M. P., Ahn, S. A., & Rousseau, M. F. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-56 · Cited by 18
Separate and Joint Associations of Shift Work and Sleep Quality with Lipids
Charles, L. E., Gu, J. K., Tinney-Zara, C. A., Fekedulegn, D. B., Claudia, C., Allison, P., Hartley, T. A., Andrew, M. E., Violanti, J. M., & Burchfiel, C. M. (2015) · Safety and Health at Work · doi:10.1016/j.shaw.2015.11.007 · Cited by 18
Xie, X., Zhang, X., Xiang, S., Yan, X., Huang, H., Tian, Y., Shou, Z., & Chen, J. (2017) · Kidney & Blood Pressure Research · doi:10.1159/000469714 · Cited by 20
Koopal, C., Visseren, F. L. J., Westerink, J., van der Graaf, Y., Ginsberg, H. N., & KEECH, A. C. (2018) · Diabetes Care · doi:10.2337/dc17-0968 · Cited by 18
Lipids, Apolipoproteins, and Inflammatory Biomarkers of Cardiovascular Risk: What Have We Learned?
Rhainds, D., Brodeur, M. R., & Tardif, J. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1114 · Cited by 19
Triglycerides: How Much Credit Do They Deserve?
Kohli, P., & Cannon, C. P. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2011.11.006 · Cited by 17
Sahebkar, A., Giua, R., Pedone, C., Ray, K., Vallejo-Vaz, A., & Costanzo, L. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.06.011 · Cited by 18
Atherogenic Dyslipidemia and Combination Pharmacotherapy in Diabetes: Recent Clinical Trials
Hamilton, S. J., & Watts, G. F. (2013) · The Review of Diabetic Studies · doi:10.1900/rds.2013.10.191 · Cited by 16
Two novel rare variants of APOA5 gene found in subjects with severe hypertriglyceridemia
Pisciotta, L., Fresa, R., Bellocchio, A., Guido, V., Oliva, C. P., Calandra, S., & Bertolini, S. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.08.001 · Cited by 17
APOA5 genetic and epigenetic variability jointly regulate circulating triacylglycerol levels
Oliva, I., Guardiola, M., Vallvé, J.-C., Ibarretxe, D., Plana, N., Masana, L., Monk, D., & Ribalta, J. (2016) · Clinical Science · doi:10.1042/cs20160433 · Cited by 17
Reimund, M., Wolska, A. T., Risti, R., Wilson, S. R., Sviridov, D. O., Remaley, A. T., & Lõokene, A. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.08.130 · Cited by 18
Li, H., Ma, J., Zheng, D., Li, X., Guo, X., Wang, J., & Su, P. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01591-w · Cited by 17
Ferrara, M., Umlauf, A., Sanders, C., Meyer, J. M., McCutchan, J. A., Duarte, N. A., Atkinson, J. H., Grant, I., & Ellis, R. J. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.04.015 · Cited by 17
Kundi, H., Korkmaz, A., Balun, A., Çiçekçioğlu, H., Kızıltunç, E., Gürsel, K., Çetın, M., Örnek, E., & İleri, M. (2017) · Angiology · doi:10.1177/0003319716689366 · Cited by 18
Are Elevated Serum Triglycerides Really a Risk Factor for Coronary Artery Disease?
Reiner, Ž. (2015) · Cardiology · doi:10.1159/000381304 · Cited by 17
Li, Y., Peng, J., Hou, F., & Zhou, Y. (2018) · Journal of Medical Systems · doi:10.1007/s10916-018-1119-y · Cited by 16
Triglycerides and Cardiovascular Outcomes—Can We REDUCE-IT ?
Pradhan, A. K., Bhandari, M., Vishwakarma, P., & Sethi, R. (2020) · International Journal of Angiology · doi:10.1055/s-0040-1701639 · Cited by 18
Chou, W., Chen, W.-T., & Shen, C. (2022) · npj Genomic Medicine · doi:10.1038/s41525-021-00279-5 · Cited by 16
Meeks, K. A. C., Bentley, A. R., Agyemang, C. O., Galenkamp, H., van den Born, B. H., Hanssen, N. M. J., Doumatey, A. P., Adeyemo, A., & Rotimi, C. N. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104548 · Cited by 15
Hypertriglyceridemia is associated with platelet hyperactivation in metabolic syndrome patients
Wang, T., Xu, J., Fu, L., & Li, L. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13508 · Cited by 17
Mendelian randomisation, triglycerides, and CHD
Paré, G., & Anand, S. S. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60659-9 · Cited by 16
Al-Hashmi, K., Al-Zakwani, I. S., Almahmeed, W. A., Arafah, M., Al-Hinai, A. T., Shehab, A. M., Tamimi, O. A., Alawadhi, M., Herz, S. A., Anazi, F. A., et al. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.12.021 · Cited by 16
Arutyunov, G. P., Boytsov, S. A., Voyevoda, M. I., Gurevich, V. S., Drapkina, O. M., Kukharchuk, V. V., Ai, M., Sergiyenko, I. V., Shestakova, M. V., Aliyeva, A. S., et al. (2019) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2019-15-2-282-288 · Cited by 17
Wang, J., Sun, Q., An, Y., Liu, J., Leng, S., & Wang, G. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.951635 · Cited by 15
A Review on Metaanalysis of Biomarkers: Promises and Pitfalls
Lewington, S., Bragg, F., & Clarke, R. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2012.184226 · Cited by 15
The triglyceride to HDL-cholesterol ratio and chronic graft failure in renal transplantation
Anderson, J. L. C., Bakker, S. J. L., & Tietge, U. J. F. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.01.009 · Cited by 15
Shaik, A., & Rosenson, R. S. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07168-0 · Cited by 15
Ahmed, A. E., AlSamghan, A. S., Momenah, M. A., Alqhtani, H. A., Aldawood, N. A., Alshehri, M. A., Alshehri, A. A., Alhag, S. K., Mosaad, Y. O., & Ahmed, H. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192214985 · Cited by 15
Hu, M., Mak, V. W. L., & Tomlinson, B. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.02.005 · Cited by 15
Langlois, M. R. (2012) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2011-0636 · Cited by 15
Ng, T., Ooi, E. M. M., Watts, G. F., Chan, D. C., & Barrett, P. H. R. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12243 · Cited by 15
Lipemia retinalis preceding acute pancreatitis
Horton, M., & Thompson, K. (2011) · Optometry · doi:10.1016/j.optm.2011.01.011 · Cited by 15
Mutation Screening of the APOA5 Gene in Subjects with Coronary Artery Disease
Soufi, M., Sattler, A., Kurt, B., & Schaefer, J. R. (2012) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e3182686918 · Cited by 15
Lipid trafficking in cardiovascular disease
Sposito, A. C., Zimetti, F., Barreto, J., & Zanotti, I. (2019) · Advances in clinical chemistry · doi:10.1016/bs.acc.2019.04.002 · Cited by 16
Heterogeneous properties of intermediate- and low-density lipoprotein subpopulations
Srisawasdi, P., Vanavanan, S., Rochanawutanon, M., Pornsuriyasak, P., Tantrakul, V., Kruthkul, K., & Kotani, K. (2013) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2013.06.021 · Cited by 17
GALNT2 effect on HDL-cholesterol and triglycerides levels in humans: Evidence of pleiotropy?
Paola, R. D., Marucci, A., & Trischitta, V. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.11.006 · Cited by 15
Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date
Jia, X., Koh, S., Al Rifai, M., Blumenthal, R. S., & Virani, S. S. (2020) · Vascular Health and Risk Management · doi:10.2147/vhrm.s210149 · Cited by 14
Do triglyceride-lowering drugs decrease risk of cardiovascular disease?
Maki, K. C., & Dicklin, M. R. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000424 · Cited by 14
Jackson, S. E., van Jaarsveld, C. H. M., Beeken, R. J., Gunter, M. J., Steptoe, A., & Wardle, J. (2015) · Biomarkers in Medicine · doi:10.2217/bmm.14.78 · Cited by 14
KEECH, A. C., & Jenkins, A. J. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000465 · Cited by 14
Li, J., Yang, Y., Jiao, X., Yu, H., Du, Y., Zhang, M., Hu, C., Wei, Y., & Qin, Y. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-06991-1 · Cited by 15
Oxidative Stress in Nonalcoholic Fatty Liver Disease
Marí, M., Morales, A., Colell, A., García‐Ruiz, C., & Fernández-Checa, J. C. (2015) · Oxidative stress in applied basic research and clinical practice · doi:10.1007/978-3-319-15539-5_12 · Cited by 14
Kastelein, J. J. P., Hallén, J., Vige, R., Fraser, D. A., Zhou, R., Hustvedt, S. O., Orloff, D. G., & Bays, H. E. (2016) · Cardiology · doi:10.1159/000445047 · Cited by 14
Genetic Predisposition of Human Plasma Triglyceride Concentrations
Schwarzová, L., Hubacek, J. A., & Vrablı́k, M. (2015) · Physiological Research · doi:10.33549/physiolres.933197 · Cited by 14
Pedoman Tatalaksana Dislipidemia PERKI 2013
Erwinanto, E., Santoso, A., Putranto, J. N., Tedjasukmana, P., Suryawan, R., Rifqi, S., & Kasiman, S. (2015) · Indonesian Journal of Cardiology · doi:10.30701/ijc.v34i4.385 · Cited by 14
Risk prediction with triglycerides in patients with stable coronary disease on statin treatment
Werner, C., Filmer, A., Fritsch, M., Groenewold, S., Gräber, S., Böhm, M., & Laufs, U. (2014) · Clinical Research in Cardiology · doi:10.1007/s00392-014-0740-0 · Cited by 13
Hypertriglyceridemia: molecular and genetic landscapes
Scicchitano, P., Amati, F., Ciccone, M. M., D’Ascenzi, F., Imbalzano, E., Liga, R., Paolillo, S., Pastore, M. C., Rinaldi, A., Mattioli, A. V., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126364 · Cited by 13
Lipid Disorders in People with HIV
Sarkar, S., & Brown, T. T. (2021) · Europe PMC (PubMed Central) · Cited by 13
Liang, F., Song, Y., Lin, D., He, H., Xu, J., He, X., & Wu, L. (2024) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000735 · Cited by 13
Genetic Risk Factors and Mendelian Randomization in Cardiovascular Disease
Swerdlow, D. I., Hingorani, A. D., & Humphries, S. E. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0584-x · Cited by 14
Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk
Farnier, M. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0743-8 · Cited by 14
Ho, L., Lin, F., Tseng, W., Yin, W., Wu, Y., Li, Y., Yeh, H., Chen, J., & Wu, C. (2018) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.05.020 · Cited by 12
Mszar, R., Bart, S., Sakers, A. P., Soffer, D. E., & Karalis, D. G. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041382 · Cited by 14
Metadata
- Authors
- ‡
- Affiliations
- University of Cambridge (GB)
- Corresponding author
- ‡
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2010-05
- Volume
- 375
- Issue
- 9726
- Pages
- 1634-1639
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC2867029
- OpenAlex
- W2144516660
- Cited by
- 716
- References
- 37
- Citations by year
- 2026: 10 · 2025: 24 · 2024: 29 · 2023: 29 · 2022: 47 · 2021: 49 · 2020: 53 · 2019: 55 · 2018: 50 · 2017: 36 · 2016: 51 · 2015: 51 · 2014: 48 · 2013: 45 · 2012: 47
- FWCI
- 62.17
- Type
- journal article
- Language
- en
- Update notices
- erratum (2010-07-10)
- Open access
- bronze
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Bristol Research (University of Bristol) (publishedVersion)
- Socio-Environmental Systems Modeling (acceptedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion)
- Leicester Research Archive (University of Leicester) (submittedVersion, other-oa)
- Explore Bristol Research (submittedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- British Heart Foundation
- Novartis
- Medical Research Council
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- triglycerides, coronary artery disease, APOA5, APOA5 -1131T>C polymorphism, genetic association, triglyceride concentration, HDL cholesterol, apolipoprotein A-I, apolipoprotein B, lipoprotein concentration, lipoprotein particle size, causal inference, genetic risk factors
- MeSH terms
- Apolipoprotein A-V, Apolipoproteins, Apolipoproteins A, Coronary Disease, Gene Frequency, Genotype, Humans, Lipids, Lipoproteins, HDL, Lipoproteins, LDL, Lipoproteins, VLDL, Particle Size, Promoter Regions, Genetic, Risk Factors, Triglycerides, Polymorphism, Single Nucleotide, Mendelian Randomization Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
